Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 10/20 | 0.46 |
| ▸ | FASN | P49327 | 9/20 | 0.46 |
| ▸ | BRD2 | P25440 | 1/20 | 0.42 |
| ▸ | EP300 | Q09472 | 1/20 | 0.42 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.42 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2034735 | 1.00 | BRD4 (0.46) | BRD4FASNBRD2EP300BRD3 | |
| SCHEMBL2035437 | 0.90 | BRD4 (0.50) | BRD4FASNBRD2EP300BRD3 | |
| SCHEMBL10104 | 0.88 | BRD4 (0.59) | BRD4BRD2EP300BRD3BRDT | |
| SCHEMBL10103 | 0.88 | BRD4 (0.59) | BRD4BRD2EP300BRD3BRDT | |
| SCHEMBL11909140 | 0.85 | BRD4 (0.48) | BRD4FASNBRD2EP300BRD3 | |
| SCHEMBL11909141 | 0.85 | BRD4 (0.48) | BRD4FASNBRD2EP300BRD3 | |
| SCHEMBL12631289 | 0.84 | FASN (0.57) | BRD4FASN | |
| SCHEMBL13834838 | 0.84 | FASN (0.57) | BRD4FASN | |
| SCHEMBL13835247 | 0.83 | FASN (0.65) | BRD4FASN | |
| SCHEMBL2033530 | 0.83 | FASN (0.65) | BRD4FASN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120295915-A1 | AZABENZIMIDAZOLES AS FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC | 2012-11-22 | — | — | US | disclosed |
| EP-2503890-A1 | AZABENZIMIDAZOLES AS FATTY ACID SYNTHASE INHIBITORS | GlaxoSmithKline LLC (US) | 2012-10-03 | — | — | EP | disclosed |
| WO-2011066211-A1 | AZABENZIMIDAZOLES AS FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2011-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295915-A1 | AZABENZIMIDAZOLES AS FATTY ACID SYNTHASE INHIBITORS | FASN, FADS1, COASY | BRD4 702/4885FASN 1/4885BRD2 866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.